SEGMENT AND GEOGRAPHIC INFORMATION

12 Months Ended

Dec. 31, 2013

Segment Reporting [Abstract]

SEGMENT AND GEOGRAPHIC INFORMATION

SEGMENT AND GEOGRAPHIC INFORMATION

The Company reports segment information on the "management" approach which designates the internal reporting used by management for making decisions and assessing performance as the source of the Company's reportable segments. The Company has determined that its Chief Executive Officer is the Company's chief operating decision maker ("CODM") as he is responsible for reviewing and approving investments in the Company's technology platforms and manufacturing infrastructure. Prior to 2012, the Company was organized as one reportable operating segment. Subsequent to the Acquisition, the Company's business was reorganized into two reportable operating segments for financial reporting purposes, Affymetrix Core and eBioscience.

Affymetrix Core is divided into four business units: Expression, Genetic Analysis and Clinical Applications, Life Science Reagents and Corporate. The reorganization into business units represented a fundamental change for the Company. The Expression business unit develops and markets the Company's gene expression products and services. The Genetic Analysis and Clinical Applications business unit markets the Company's genotyping platform and cytogenetics products. The Life Science Reagents business unit sells reagents, enzymes, purification kits and biochemicals used by life science researchers. The Corporate business unit is comprised primarily of incidental revenue from royalty arrangements, and field revenue from services provided to customers by the Company. The Company has concluded that its manufacturing operations are based on platforms that are used to produce various products that serve multiple applications and markets. Additionally, the business units share research, development and common corporate services that provide capital, infrastructure and functional support. Based on the facts and circumstances, the Company concluded that the four business units represent one reportable operating segment, Affymetrix Core.

The Company's other reportable operating segment, eBioscience, was acquired in the second quarter of 2012 and is operated as a separate business unit in order to minimize or avoid any disruption of services, while taking advantage of immediate opportunities to create efficiencies. eBioscience specializes in the development, manufacturing, marketing and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Acquisition allows the Company to expand addressable markets and continue to diversify the business beyond genomics discovery into cell and protein analysis.

The Company evaluates the performance of its reportable operating segments based on revenue and income (loss) from operations. Revenue is allocated to each business unit based on product codes. The eBioscience business is operated on a stand-alone basis.

The following table shows revenue and income (loss) from operations by reportable operating segment for the years ended December 31, 2013, 2012, or 2011 (in thousands):

	Year Ended December 31,
	2013			2012			2011
Revenue (a):
Affymetrix Core	$	252,164		$	258,612		$	267,474
eBioscience	78,235			37,011			—
Totals	$	330,399		$	295,623		$	267,474
Income (loss) from operations (a):
Affymetrix Core	$	528		$	(30,299	)	$	(16,641	)
eBioscience	(13,080		)	(8,792		)	—
Totals	$	(12,552	)	$	(39,091	)	$	(16,641	)

The Company reported total revenue by region as follows (in thousands):

	Year Ended December 31,
	2013		2012		2011
Customer location:
United States	$	202,323	$	171,176	$	142,508
Europe	80,844		71,526		76,286
Japan	15,511		21,039		19,989
Other	31,721		31,882		28,691
Total	$	330,399	$	295,623	$	267,474

There were no customers representing 10% or more of total revenue in 2013, 2012 or 2011.

The Company's long-lived assets other than purchased intangible assets, which the Company does not allocate to specific geographic locations as it is impracticable to do so, are composed principally of net property and equipment.

Net property and equipment, classified by major geographic areas in which the Company operates was as follows (in thousands):

	Year Ended December 31,
	2013		2012
Net property and equipment:
United States	$	13,829	$	22,203
Singapore	3,218		4,260
Europe	1,319		1,770
Other countries	305		430
Total	$	18,671	$	28,663